Document is current
Any future updates will be listed below
-
Authors
Muto, Yoshiharu https://orcid.org/0000-0002-0358-9442
Dixon, Eryn E. https://orcid.org/0000-0003-4604-7907
Yoshimura, Yasuhiro
Wu, Haojia https://orcid.org/0000-0002-7866-2544
Omachi, Kohei
Ledru, Nicolas https://orcid.org/0000-0002-9237-3634
Wilson, Parker C. https://orcid.org/0000-0001-8647-9662
King, Andrew J.
Eric Olson, N.
Gunawan, Marvin G. https://orcid.org/0000-0001-7037-417X
Kuo, Jay J. https://orcid.org/0000-0001-8741-2638
Cox, Jennifer H.
Miner, Jeffrey H. https://orcid.org/0000-0002-1510-8714
Seliger, Stephen L.
Woodward, Owen M. https://orcid.org/0000-0001-9514-2180
Welling, Paul A.
Watnick, Terry J.
Humphreys, Benjamin D. https://orcid.org/0000-0002-6420-8703
- License Information
-
More Information
Article History
Received: 10 November 2021
Accepted: 17 October 2022
First Online: 30 October 2022
Competing interests
: B.D.H. is a consultant for Janssen Research & Development, LLC, Pfizer and Chinook Therapeutics, holds equity in Chinook Therapeutics and grant funding from Chinook Therapeutics and Janssen Research & Development, LLC. O.M.W. has received grants from AstraZeneca unrelated to the current work. J.H.M. has received funding from Chinook Therapeutics unrelated to the current work. S.S. has received grant funding from Otsuka, Palladio Biosciences, Kadmon Corporation, Sanofi, and Reata Pharmaceuticals. A.J.K., E.O., M.G., J.K., and J.H.C. are employees and stock holders of Chinook Therapeutics. The remaining authors declare no competing interests.
